Biogen, Sage secure FDA approval for Zurzuvae to treat postpartum depression
Zurzuvae causes central nervous system (CNS) depressant effects, and people who take the drug should not drive a…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 Aug 23
Zurzuvae causes central nervous system (CNS) depressant effects, and people who take the drug should not drive a…
04 Aug 23
The partnership builds upon the companies' existing collaboration, which centres around the development and commercialisation of pelacarsen
02 Aug 23
LX2020 is an AAV-based gene therapy that works by intravenously delivering a functional PKP2 gene to increase the…
01 Aug 23
The combination of Jemperli and chemotherapy consisting of carboplatin and paclitaxel has been indicated for patients having primary…
28 Jul 23
The EC approval expands the Soliris initial indication, to treat certain adults with refractory generalised myasthenia gravis (gMG)…
21 Jul 23
Previously known as AV7909, the Cyfendus vaccine is comprised of Anthrax Vaccine Adsorbed (AVA) and an additional adjuvant,…
14 Jul 23
Opill is said to be the first oral contraceptive medicine to be approved for over-the-counter (OTC) use in…
12 Jul 23
Columvi is a T-cell-engaging bispecific antibody engineered to have one region that binds to CD3, a protein on…
07 Jul 23
Leqembi is a humanised immunoglobulin gamma 1 (IgG1) monoclonal antibody therapy, initially approved to treat AD in adults,…
05 Jul 23
The EC authorisation is supported by positive data from the Phase ½ FOENIX-CCA2 clinical trial, in which Lytgobi…